Treatments that target a fragment of the mutant protein that causes Huntington's disease might be more effective than treatments—now in clinical trials—that target the whole protein but leave this ...
An expert involved in the first successful gene therapy trial for Huntington's Disease discusses the trial results and ...
Researchers found that targeting a protein fragment, huntingtin 1a, restored baseline gene activity and reduced aggregate ...
Findings from preclinical studies could point to therapeutic strategies for Huntington’s disease, as well as other neurodegenerative disorders and potentially cancer.
Huntington's disease is a devastating brain disorder that slowly robs people of movement, memory, and personality. It is caused by a toxic protein that builds in brain cells and ultimately kills them.
UniQure needs to run another study to prove its gene therapy "actually helps people with Huntington's disease," a senior FDA official said. The official said UniQure is the "latest company to make a ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Actor and comedian Will Forte often played MacGruber, a parody of the can-fix-anything TV ...
A senior FDC official said the product is a “failed therapy” and confirmed that regulators have asked uniQure to run a new trial to prove the therapy actually helps Huntington’s patients. The ...
Gene Therapy Meets Regulatory Reality: The FDA–uniQure Clash Over a Promising Huntington’s Treatment
The FDA’s dispute with biotech firm uniQure over Huntington’s gene therapy highlights growing tensions between innovation, safety, and rare-disease drug approvals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results